中药大品种二次开发的安全性关注及再评价意义

Significance of re-evaluation and development of Chinese herbal drugs

中药新药研究包括新药创制与二次开发2个重要方向,名优中药的二次开发既要重视中医药理论指导,又要发挥中医药特色和优势。目前名优中药的二次开发重在工艺改造、质量标准控制、有效物质基础探寻和临床定位研究等方面,缺乏安全性的系统管理和评价,尚未针对中药大品种二次开发的安全性建立相关评价体系。该文从中药大品种安全性问题的产生原因、产生中药安全性隐患的主要大品种及毒性靶器官、中药大品种二次开发安全性评价的薄弱环节、二次开发安全性评价的思路和必要性等方面进行概述;同时提出安全性研究既要重视符合GLP要求的规范性评价,更应充分考虑中药大品种综合作用的自身特点,而将安全性研究贯穿于新药研发中的整个过程。以期引起人们对名优中成药二次开发安全性研究的高度关注。

The research of new herbal drugs involves in new herbal drugs development and renew the old drugs.It is necessary to research new herbal drugs based on the theory of traditional Chinese medicine(TCM).The current development of famous TCM focuses on the manufacture process,quality control standards,material basis and clinical research.But system management of security evaluation is deficient,the relevant system for the safety assessment TCM has not been established.The causes of security problems,security risks,target organ of toxicity,weak link of safety evaluation,and ideas of safety evaluation are discussed in this paper.The toxicology research of chinese herbal drugs is necessary based on standard of good laboratory practices(GLP),the characteristic of Chinese herbal drugs is necessary to be fully integrated into safety evaluation.The safety of new drug research is necessary to be integrated throughout the entire process.Famous Chinese medicine safety research must be paid more attention in the future.